Kiniksa Pharmaceuticals Ltd (KNSA) - Net Assets
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has net assets worth $654.15 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($896.11 Million) and total liabilities ($241.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check KNSA strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $654.15 Million |
| % of Total Assets | 73.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | 206.75% |
| 10-Year Change | N/A |
| Growth Volatility | 46.27 |
Kiniksa Pharmaceuticals Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see KNSA market cap overview.
Annual Net Assets for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual net assets of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. Also explore how fast is Kiniksa Pharmaceuticals Ltd growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $567.61 Million | +29.46% |
| 2024-12-31 | $438.44 Million | -0.09% |
| 2023-12-31 | $438.84 Million | +10.78% |
| 2022-12-31 | $396.15 Million | +114.09% |
| 2021-12-31 | $185.04 Million | -40.68% |
| 2020-12-31 | $311.94 Million | +38.38% |
| 2019-12-31 | $225.42 Million | -19.28% |
| 2018-12-31 | $279.27 Million | +411.31% |
| 2017-12-31 | $-89.71 Million | -248.62% |
| 2016-12-31 | $-25.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kiniksa Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43601300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.00K | 0.00% |
| Other Comprehensive Income | $-25.00K | 0.00% |
| Other Components | $1.03 Billion | 181.42% |
| Total Equity | $567.61 Million | 100.00% |
Kiniksa Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Haige Communications Group Incorporated Co
SHE:002465
|
$3.63 Billion |
|
Sai MicroElectronics Inc
SHE:300456
|
$3.63 Billion |
|
Shanghai Zhonggu Logistics Co Ltd
SHG:603565
|
$3.63 Billion |
|
Charoen Pokphand Foods Public Company Limited
F:NVAV
|
$3.63 Billion |
|
Anhui Zhongding Sealing Parts Co Ltd
SHE:000887
|
$3.63 Billion |
|
Centre Testing Intl Shenzhen
SHE:300012
|
$3.63 Billion |
|
Wockhardt Limited
NSE:WOCKPHARMA
|
$3.63 Billion |
|
Rubis SCA
PA:RUI
|
$3.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kiniksa Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 438,436,000 to 567,606,000, a change of 129,170,000 (29.5%).
- Net income of 59,005,000 contributed positively to equity growth.
- Share repurchases of 7,730,000 reduced equity.
- Other comprehensive income increased equity by 138,000.
- Other factors increased equity by 77,757,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $59.01 Million | +10.4% |
| Share Repurchases | $7.73 Million | -1.36% |
| Other Comprehensive Income | $138.00K | +0.02% |
| Other Changes | $77.76 Million | +13.7% |
| Total Change | $- | 29.46% |
Book Value vs Market Value Analysis
This analysis compares Kiniksa Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.79 | $75.15 | x |
| 2017-12-31 | $-2.76 | $75.15 | x |
| 2018-12-31 | $-6.57 | $75.15 | x |
| 2019-12-31 | $4.17 | $75.15 | x |
| 2020-12-31 | $5.04 | $75.15 | x |
| 2021-12-31 | $2.70 | $75.15 | x |
| 2022-12-31 | $5.63 | $75.15 | x |
| 2023-12-31 | $6.10 | $75.15 | x |
| 2024-12-31 | $6.14 | $75.15 | x |
| 2025-12-31 | $7.19 | $75.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kiniksa Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.40%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.71%
- • Asset Turnover: 0.89x
- • Equity Multiplier: 1.35x
- Recent ROE (10.40%) is above the historical average (-15.88%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.40 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-55.90 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-83.80 Million |
| 2019 | -71.81% | 0.00% | 0.00x | 1.13x | $-184.41 Million |
| 2020 | -51.74% | -2094.77% | 0.02x | 1.12x | $-192.57 Million |
| 2021 | -85.35% | -409.72% | 0.17x | 1.26x | $-176.43 Million |
| 2022 | 46.29% | 83.28% | 0.48x | 1.16x | $143.75 Million |
| 2023 | 3.21% | 5.21% | 0.51x | 1.20x | $-29.80 Million |
| 2024 | -9.85% | -10.21% | 0.73x | 1.32x | $-87.04 Million |
| 2025 | 10.40% | 8.71% | 0.89x | 1.35x | $2.24 Million |
Industry Comparison
This section compares Kiniksa Pharmaceuticals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $290,420,616
- Average return on equity (ROE) among peers: -51.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kiniksa Pharmaceuticals Ltd (KNSA) | $654.15 Million | 0.00% | 0.37x | $3.63 Billion |
| Aurora Cannabis Inc (ACB) | $1.08 Million | -29.24% | 0.07x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $140.89 Million | 0.00% | 0.10x | $138.64 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $241.89 Million |
| Alkermes Plc (ALKS) | $1.11 Billion | -4.33% | 0.82x | $7.72 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $3.58 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $5.80 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.00 Million | -54.00% | 0.38x | $279.44 Million |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more